UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011129
Receipt number R000013038
Scientific Title Effect of rivaroxaban for anti-atherosclerotic response in atrial fibrillation patients
Date of disclosure of the study information 2013/07/05
Last modified on 2013/07/05 19:22:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of rivaroxaban for anti-atherosclerotic response in atrial fibrillation patients

Acronym

Effect of rivaroxaban for anti-atherosclerotic response in atrial fibrillation patients

Scientific Title

Effect of rivaroxaban for anti-atherosclerotic response in atrial fibrillation patients

Scientific Title:Acronym

Effect of rivaroxaban for anti-atherosclerotic response in atrial fibrillation patients

Region

Japan


Condition

Condition

atrial fibrillation

Classification by specialty

Medicine in general Cardiology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to examine the effect of rivaroxaban for anti-atherosclerotic actions

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Change of inflammatory cytokine
Transition of blood coagulation and fibrinolysis

Key secondary outcomes

Evaluation of IMT by carotid artery echo
Evaluation of atherosclerotic plaque volume and character


Base

Study type


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Pescribe rivaroxaban15mg or 10mg once daily , according to renal function

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

nonvalvular atrial fibrillation

Key exclusion criteria

High risk for bleeding
Liver dysfunction
Renal failure
Pregnancy
severe infection and trauma, perioperation
Treatment with HIV protease inhibitors
Treatment with azole antifungal agents
History of allergy to rivaroxaban
Ineligible in the opinion of investigators

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ichiro Michshita

Organization

Yokohama Sakae Kyosai Hospital

Division name

Division of Cardiology, Department of Internal Medicine

Zip code


Address

132 Katsura-cho, Sakae-ku, Yokohama, 247-8581, Japan

TEL

045-891-2171

Email



Public contact

Name of contact person

1st name
Middle name
Last name Sei Nakata

Organization

Yokohama Sakae Kyosai Hospital

Division name

Division of Cardiology, Department of Internal Medicine

Zip code


Address

132 Katsura-cho, Sakae-ku, Yokohama, 247-8581, Japan

TEL

045-891-2171

Homepage URL


Email

i-michishita@yokohamasakae.jp


Sponsor or person

Institute

Yokohama Sakae Kyosai Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 07 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2012 Year 10 Month 03 Day

Date of IRB


Anticipated trial start date

2012 Year 10 Month 03 Day

Last follow-up date

2014 Year 12 Month 31 Day

Date of closure to data entry

2014 Year 12 Month 31 Day

Date trial data considered complete

2015 Year 05 Month 31 Day

Date analysis concluded

2015 Year 05 Month 31 Day


Other

Other related information



Management information

Registered date

2013 Year 07 Month 05 Day

Last modified on

2013 Year 07 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013038